Hyperlipidemia Due to Oxymetholone Therapy
Occurrence in a Long-Term Hemodialysis Patient
- Robert D. Reeves, PhD;
- Manford D. Morris, PhD;
- Galen L. Barbour, MD
Abstract
Marked hypertriglyceridemia and hypercholesterolemia accompanied by angina and a left cerebral thrombosis occurred in a long-term hemodialysis patient following 5 1/2 weeks of oral treatment with oxymetholone, 100 mg/day, a synthetic androgen. After androgen therapy was discontinued, over a three-month period, plasma lipid values progressively decreased below pretreatment values, and clinical symptoms disappeared. During rechallenge with oxymetholone, serum lipid values increased substantially, and the lipoprotein pattern changed from a type IV to a type V. Detailed lipid studies showed subnormal postheparin lipolytic activity and a fast-migrating pre-β-lipoprotein in the very-low-density lipoproteins (VLDL) fraction. Because of the data linking lipid abnormalities to atherosclerosis and the acceleration of atherosclerosis in long-term hemodialysis patients, great caution should be exercised in administering androgenic steroids to these patients.
(JAMA 236:469-472, 1976)
Footnotes
-
Reprint requests to Department of Medicine, Nephrology Section, Veterans Administration Hospital, 300 E Roosevelt Rd, Little Rock, AR 72206 (Dr Reeves).
